Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

Core Viewpoint - Moleculin Biotech, Inc. has received a notice of allowance for a patent in Japan related to the preparation of liposomal Annamycin, which is expected to enhance its intellectual property position and support the development of its non-cardiotoxic therapy for acute myeloid leukemia [1][2][3] Group 1: Patent and Intellectual Property - The Japan Patent Office has allowed claims for a patent application covering methods for reconstituting liposomal Annamycin, ensuring consistent dosing and stability for intravenous administration [2] - This patent allowance complements existing U.S. and European patent protections, with additional applications pending in major jurisdictions worldwide [2][3] Group 2: Product Development and Clinical Trials - Annamycin, also known as naxtarubicin, is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and is positioned to be the first non-cardiotoxic anthracycline approved for clinical use [2][4] - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML [5] - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML, as well as Orphan Drug Designation from the EMA [3][5] Group 3: Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapies for hard-to-treat tumors and viruses, with Annamycin as its lead program [4][6] - The company is also developing WP1066, an immune/transcription modulator targeting various cancers, and has a portfolio of antimetabolites for potential treatment of pathogenic viruses and certain cancer indications [6]